Sort   by:  
 Page size 
TranscriptomicsThe role of p53 in the regulation of miRNA expression profiling
To understand the role of p53 in regulating stem cell population (CD24-CD44+) and stemness-associated miRNAs, we first compared miRNA expression profiles between human mammary epithelial cells knocked-down p53 and control cells. We then cross-referenced p53-regulated miRNAs with stemness-associated ...
ORGANISM(S): Homo sapiens 
2011-02-01 | E-GEOD-25035 | biostudies-arrayexpress
TranscriptomicsmiRNA expression profiling in human mammary epithelial cell (HMEC) CD24-CD44+ and non-CD24-CD44+ cell populations
To understand the role of p53 in regulating stem cell population (CD24-CD44+) and stemness-associated miRNAs, we first compared miRNA expression profiles between human mammary epithelical cells knocked-down p53 and control cells. We then cross-referenced p53-regulated miRNAs with stemness-associated...
ORGANISM(S): Homo sapiens 
2011-02-01 | E-GEOD-25036 | biostudies-arrayexpress
TranscriptomicsNext-Generation Sequencing for Whole Transcriptome Analysis in Scrambled Control and EGFR Knockdown Cells Cultured under Normoxia and Hypoxia
Purpose: The goal of this study is to identify the mRNA clusters that are regulated by EGFR under normoxia or hypoxia. Method: Total RNAs were extracted from HeLa cells expressing scrambled control or EGFR shRNA-E1 that cultured under normoxia or hypoxia (1% O2) for 24h. Customized Next-Generation R...
ORGANISM(S): Homo sapiens 
2013-10-01 | E-GEOD-44801 | biostudies-arrayexpress
TranscriptomicsAffymetrix SNP array data for EZH2 mediated gene copy number change in breast tumor initiating cells
EZH2 is shown to be involved in regulation of DNA damage repair which may contribute to development of breast tumor initiating cells. To identify genomic aberrations regulated by EZH2 expression, we performed genome wide copy number variation analysis in breast tumor initiating cells expressing EZH2...
ORGANISM(S): Homo sapiens 
2010-09-17 | E-GEOD-24144 | biostudies-arrayexpress
UnknownDurvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Not available
S-EPMC10824389 | biostudies-literature
Sort   by:  
 Page size